Wipfli Financial Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Wipfli Financial Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$27K	Buy	+619	New	+$26.1K	﹤0.01%	1431

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wipfli Financial Advisors's IONS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2022: 619 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #1431 among its holdings.

349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

Wipfli Financial Advisors held 619 shares of Ionis Pharmaceuticals worth $27K as of Q3 2022.
Ionis Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Ionis Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1431 holding.
349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.